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Mediator subunit MED1 is a T3-dependent and T3-independent 
coactivator on the thyrotropin β gene promoter 
 
 
ABSTRACT 
 
The MED1 subunit of the Mediator transcriptional coregulator complex is a nuclear 
receptor-specific coactivator. A negative feedback mechanism of thyroid-stimulating 
hormone (TSH, or thyrotropin) expression in the thyrotroph in the presence of 
triiodothyronine (T3) is employed by liganded thyroid hormone receptor β (TRβ) on the 
TSHβ gene promoter, where conventional histone-modifying coactivetors act as 
corepressors. We now provide evidence that MED1 is a ligand-dependent positive 
cofactor on this promoter. TSHβ gene transcription was attenuated in MED1 mutant 
mice in which the nuclear receptor-binding ability of MED1 was specifically disrupted. 
MED1 stimulated GATA2- and Pit1-mediated TSHβ gene promoter activity in a 
ligand-independent manner in cultured cells. MED1 also stimulated transcription from 
the TSHβ gene promoter in a T3-dependent manner. The transcription was further 
enhanced when the T3-dependent corepressors SRC1, SRC2, and HDAC2 were 
downregulated. Hence, MED1 is a T3-dependent and -independent coactivator on the 
TSHβ gene promoter.  
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Introduction  
 
In the anterior pituitary thyrotroph, a well-known negative feedback mechanism 
regulates thyroid stimulating hormone (TSH, or thyrotropin) production in response to 
triiodothyronine (T3) concentration. The mechanism involves a negative (n) 
TR-responsive element (TRE) (nTRE) in the TSHβ gene promoter. There is a switch in 
cofactor function on nTRE, wherein the histone-modifying cofactors (SRC1 and SRC2) 
that act as coactivators on conventional TREs act as corepressors, and the histone 
deacetylase (NCoR) that acts as a corepressor on conventional TREs acts as a 
coactivator [1-3; reviewed in 4]. In addition, HDAC2 acts as a ligand-dependent 
corepressor on the TSHβ gene promoter [5]. Besides the nTRE in the TSHβ gene 
promoter, there appears to be a mechanism for T3-dependent transcriptional repression 
through the action of thyroid hormone receptor β (TRβ) that is not associated with DNA 
but with GATA2 [6].  
  
We have previously shown through Med1 knockout mouse studies that MED1 is a 
positive cofactor on the TSHβ gene promoter in the pituitary thyrotroph. Med1−/− mice 
are lethal, and Med1
+/−
 mice suffer from pituitary hypothyroidism because of reduced 
TSHβ gene transcription [7]. Although the mechanism underlying this mouse phenotype 
is not known, previous reports suggest a ligand-independent mechanism on the TSHβ 
gene promoter, in which MED1 interacts with GATA2 and Pit1 and coactivates GATA2- 
and Pit1-initiated transactivation [8]. On the other hand, the T3-dependent, 
TRβ-mediated function of MED1 on the TSHβ gene promoter (or nTRE) has not been 
described.  
  
We have developed mutant mice in which the nuclear receptor-binding ability of MED1 
was specifically disrupted. We knocked in cDNA encoding mutant MED1 with two 
LxxLL nuclear receptor recognition motifs modified to LxxAA (MED1(LX) KI mice) 
[9]. In this study, we show that TSHβ gene transcription in these mice is reduced, 
indicating that MED1 is a T3-dependent coactivator on the TSHβ gene promoter. This 
phenotype was confirmed through cell biological analyses.  
  
 
Materials and methods  
 
Mice 
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MED1(LX) KI mice [9], backcrossed at least 10 times with C57BL6, were used for 
experiments. All animal experiments were performed according to National Institutes of 
Health (NIH) guidelines in the Rockefeller University Laboratory Animal Research 
Center or the institutional guidelines of the Animal Research Center, Kobe University, 
Japan.  
  
Cell culture 
Stable lines of Med1
+/+
 p53
−/−
 and Med1
−/−
 p53
−/−
 mouse embryonic fibroblasts 
(MEFs), established from embryonic day 10.0 (E10.0) embryos derived from a single 
crossing of Med1
+/−
 p53
+/−
 male and Med1
+/−
 p53
+/−
 female mice on a C57BL6 
background, have been described [10]. Med1
+/+
 and Med1
−/−
 MEFs (with p53
−/−
) and 
CV-1 cells, distributed by RIKEN BRC through the National Bio-Resource of the 
Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS at 37°C.  
  
Plasmids 
Mouse (m) GATA2 and human (h) Pit1 cDNAs were kindly provided by M. Yamamoto 
and Y. Okimura, respectively. These cDNAs (alone or fused with VP16) were inserted 
into pcDNA3.1(+) (Invitrogen). Gal4-fused truncated hMED1 cDNA was subcloned in 
pCDM8 (Invitrogen). hMED1, hMED1(LX mutant), and siRNA-resistant hMED1 
cDNAs in pIRESneo (Clontech) were described previously [11]. siRNA-resistant 
hMED1(1-530) in pIRESneo was likewise prepared by site-directed mutagenesis. hTRβ 
cDNA was prepared by RT-PCR and cloned in pcDNA3.1(+).  
  
For luciferase reporters, the human TSHB promoter (−128 to +40) was amplified from 
genomic DNA using KOD FX (Toyobo, Japan) and cloned into the firefly luciferase 
reporter plasmid pGL4.10 to create TSHB-LUC. The reporter containing five Gal4 
binding sites (5×Gal4-LUC) has been described [10].  
  
Luciferase reporter assay and mammalian two-hybrid assay 
For luciferase reporter assays, cells (2 × 104) in 24-well plates were transfected with 
pcDNA3.1-mGATA2 (80 ng), pcDNA3.1-hPit1 (40 ng), pIRESneo-hMED1 (120 ng), 
pIRESneo-mutant hMED1 (120 ng), and/or pcDNA3.1-hTRβ (30 ng), without or with 
10−7 M 3,3′,5-triiodo-L-thyronine (T3) (Sigma), together with TSHB-LUC (160 ng) and 
the Renilla control luciferase vector (5 ng) using Lipofectamine2000 (Invitrogen). In 
some experiments, 5 nM siRNA (Silencer® Select Pre-designed siRNA; Applied 
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Biosystems) was cotransfected. After 48 h, reporter activity was measured using the 
Dual-Luciferase Reporter Assay System (Promega) and normalized to the activity of the 
control Renilla luciferase [10].  
  
Mammalian two-hybrid assays were similarly performed by transfection with 
Gal4-fused expression vector (10 ng), VP16-fused expression vector (200 ng), and 
5×Gal4-LUC (100 ng), together with the Renilla control luciferase vector (5 ng).  
  
Quantification of mRNA 
For northern blot analysis, mRNA (10 μg) from five pooled male pituitaries was used 
[7]. The probes used were a 0.4-kb fragment of mouse TSHβ cDNA, a 0.6-kb fragment 
of mouse growth hormone cDNA, a 0.5-kb fragment of mouse TSHα cDNA, a 0.3-kb 
fragment of mouse FSHβ cDNA, a 0.3-kb fragment of mouse LHβ cDNA, and a 0.5-kb 
fragment of human actin cDNA. Signal intensities were quantified with a STORM840 
image analyzer (Molecular Dynamics).  
  
For quantitative PCR (qPCR), total RNA (1 μg) was used to prepare cDNA with the 
ReverTra Ace qPCR RT kit (Toyobo, Japan). The expression of various genes was 
identified by qPCR (StepOnePlus™ Real-Time PCR system; Applied Biosystems). 
Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference 
marker. The sequences of the primers and the PCR conditions used for amplification are 
available upon request.  
  
Western blot analysis and measurement of serum hormone levels 
For western blot analysis, total cell lysates were separated by SDS-PAGE, blotted onto a 
nitrocellulose membrane, and probed with polyclonal antibodies against MED1 (M255; 
Santa Cruz Biotechnology), SRC1 (M341; Santa Cruz Biotechnology), SRC2 (F2; 
Santa Cruz Biotechnology), HDAC2 (AB394; Sigma), and β-actin (BioLegend). Serum 
levels of free T3 and free thyroxine (T4) were measured by solid phase 125I 
radioimmunoassay using Coat-a-Count Free T3 and Coat-a-Count Free T4 (Diagnostic 
Products Corporation, CA).  
  
Statistical analysis 
All assays were performed in triplicate in at least three separate experiments. The 
significance of the differences between independent means was assessed by one-way 
ANOVA or Student’s t-test. We considered a P value of <0.05 statistically significant.  
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Results  
 
Dysfunction of the pituitary-thyroid axis in MED1(LX) KI mice 
We previously reported that Med1
+/−
 mice exhibit hypothyroidism because of the 
reduced level of TSHβ mRNA in the pituitary [7]. To determine if the mechanism of 
hypothyroidism in the heterozygous knockouts is related to the function of TRβ or 
another activator(s), we analyzed the pituitary-thyroid axis of MED1(LX) KI mice. The 
free T4 serum levels were slightly but significantly lower in MED1(LX) homozygous 
KI males than in wild-type or heterozygous KI male siblings, but the free T3 serum 
levels were comparable. In contrast, both the free T3 and free T4 serum levels were 
comparable in MED1(LX) heterozygous KI and wild-type male siblings (Fig. 1A). 
These findings indicate a reduced thyroid hormone reservoir (but essentially a euthyroid 
condition) specifically in MED1(LX) homozygous KI mice.  
  
Thyroid hormone production in the thyroid is stimulated by pituitary TSH, but subject 
to a strict feedback mechanism via T3-bound TRβ. In order to determine the organ 
responsible for the low thyroid hormone reservoir, TSH production in the pituitary was 
analyzed by assessing the mRNA levels of the two TSH subunits in the pituitary. In 
multiple northern blot analyses, TSHβ mRNA levels were significantly lower in 
MED1(LX) homozygous KI males, whereas TSHα mRNA levels were comparable (Fig. 
1B). By contrast, the mRNA levels of other pituitary hormones that use the common α 
subunit, including follicle stimulating hormone (FSH) β and luteinizing hormone (LH) β, 
were normal (Fig. 1B). Taken together, these findings indicate that the observed low 
thyroid hormone reservoirs in MED1(LX) homozygous KI mice are due to the reduced 
level of TSHβ mRNA in the pituitary and that the T3-dependent interaction of MED1 
with TRβ has a crucial role in the normal transcriptional control of TSHβ in the 
pituitary.  
 
MED1 is a positive cofactor for GATA2 and Pit1 on the TSHB promoter 
GATA2 and Pit1 bind to the TSHβ gene promoter and activate transcription [12]. The 
involvement of MED1 in this process may underlie the pituitary hypothyroidism 
observed in Med1
+/−
 mice. We analyzed the role of MED1 in TSHβ gene promoter 
activation using a series of luciferase reporter assays in cell culture. In CV-1 cells, in 
agreement with previous studies, TSHβ gene promoter activity was upregulated by 
GATA2 or Pit1, and the reporter activity was further enhanced when GATA2 and Pit1 
were added together (Fig. 2A). In Med1
−/−
 MEFs, enhanced reporter activity via 
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GATA2 and Pit1 was observed in the absence of MED1. When MED1 was 
re-introduced into these cells, the reporter activity was further enhanced (Fig. 2B). 
These data indicate that MED1 is a positive cofactor for GATA2 and/or Pit1, but that 
transcription can also occur in the absence of MED1.  
  
In GST pull-down assays, GATA2 and Pit1 interacted with MED1 at its N-terminus [8]. 
We also assessed the intracellular interactions by mammalian two-hybrid assays using 
Med1
−/−
 MEFs. Both GATA2 and Pit1 specifically interacted with MED1(1–530), the 
smallest fragment of MED1 that integrates into the Mediator complex [13] (Fig. 2C, D). 
Thus, MED1(1–530) appears to be the interface between GATA2/Pit1 and MED1.  
  
Similar assays using Med1
+/+
 MEFs and the TSHB promoter-reporter were used to 
confirm the role of MED1 in GATA2/Pit1 regulation of TSHβ gene transcription. When 
MED1 was knocked down in the presence of GATA2 and Pit1 in these cells, reporter 
activity was attenuated. However, when siRNA-resistant full-length MED1 or 
MED1(1–530) was reintroduced, reporter activity was recovered (Fig. 2E–G). These 
observations indicate that MED1 is a coactivator for GATA2 and Pit1 on the TSHβ gene 
promoter. 
 
MED1 is a positive cofactor for liganded TRβ on the TSHβ gene promoter 
Because TSHβ gene transcription was attenuated in MED1(LX) KI mice, we asked if 
MED1 enhanced T3-dependent transcription on the TSHβ gene promoter, as it does on 
promoters that possess a conventional TRE. To this end, we first performed promoter 
assays using Med1
−/−
 MEFs in the presence of TRβ, but without exogenous GATA2 and 
Pit1, in a setting where T3 did not change the promoter activity (Fig. 3A). When 
wild-type MED1 was added, the T3-independent reporter activity was upregulated 
2.3-fold. In the presence of MED1 and T3, the reporter activity was further upregulated 
4.3-fold (Fig. 3A). However, ligand-dependent activation was not observed when 
LX-mutant MED1 or MED1(1–530) was introduced (Fig. 3A). These results indicate 
that T3-dependent transactivation on the TSHβ gene promoter is dependent on the 
MED1 LxxLL-mediated interaction between MED1 and liganded TRβ.  
  
We next asked if T3-dependent transactivation occurs concomitant with elevated levels 
of GATA2 and Pit1. In the setting of exogenously added GATA2, Pit1, and TRβ, but in 
the absence of MED1, reporter activity was mildly attenuated (0.8-fold) when T3 was 
added (Fig. 3D). However, when MED1 was added, the reporter activity was enhanced 
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(1.4-fold) in a T3-dependent matter. SRC1 and SRC2 act cooperatively as T3-dependent 
corepressors on the TSHβ gene promoter [2]. HDAC2 is also recruited to liganded TRβ 
on the TSHβ gene promoter and is involved in transcriptional repression [5]. To exclude 
the interference of these negative cofactors, we reduced the endogenous levels of the 
cofactors by cotransfection with their respective siRNAs and tested reporter activity. 
When SRC1 and SRC2 and/or HDAC2 were knocked down, the T3-dependent 
transactivation was significantly enhanced (up to 2-fold) compared to the reporter 
activity in the absence of the siRNAs for these cofactors (Fig. 3B–D). These results 
clearly indicate that MED1 is a T3-dependent positive cofactor on the TSHβ gene 
promoter.  
 
 
Discussion  
 
We determined a role for MED1 in both T3-dependent and T3-independent 
transcriptional activation on the promoter of the gene encoding TSHβ. This implies that 
MED1 is an important positive regulator in the pituitary thyrotroph that maintains the 
homeostasis of thyroid hormone by a mechanism distinct from the p160 family 
cofactors.  
  
We propose two mechanisms for the recruitment of MED1 to the TSHβ gene promoter. 
N-terminal MED1(1–530) mediates recruitment via interaction with GATA2 and/or Pit1 
in a T3-independent manner, and the LxxLL nuclear receptor recognition motif of 
MED1 serves as an interface for the interaction with liganded TRβ in a T3-dependent 
manner (Fig. 4). The existence of a T3-dependent coactivator on this promoter suggests 
an interesting model for the transcriptional control of negative feedback in the 
thyrotroph. While the manner in which HDAC2 is recruited to liganded TRβ has not 
been demonstrated, the interaction of MED1 and the p160 family of coactivators with 
the AF2 domain of nuclear receptors is mutually exclusive [14]. Therefore, the 
interaction of the positive cofactor MED1 and a p160 family negative cofactor with 
liganded TRβ is competitive. When MED1 interacts with liganded TBβ, 
LxxLL-mediated recruitment of MED1 to the promoter could enhance the concomitant 
or subsequent association of MED1(1–530) with GATA2/Pit1, thus further stabilizing 
the recruitment of Mediator and the formation of the preinitiation complex (PIC) for 
transcriptional initiation. SRC1/SRC2 associated with liganded TRβ could block 
Mediator and the functional formation of PIC on the promoter. On the other hand, when 
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SRC1/SRC2 is downregulated, MED1-led Mediator recruitment becomes dominant and 
contributes to an elevated TSH level.   
  
The location of nTRE corresponds to the transcription initiation site (Fig. 4), raising the 
question of whether TRβ stably associates with DNA during promoter melting induced 
by PIC. At the nTRE located within the Necdin gene promoter, TRβ dissociates from 
DNA during transcription [15]. In this regard, the hypothesis of an activator switch 
(TRβ to GATA2/Pit1) during MED1-led Mediator recruitment to this promoter is 
attractive and should be tested in the future.  
  
In human diseases with mutant TRβ that result in generalized resistance to thyroid 
hormone and in mouse models lacking TRβ (and/or TRα), TSHβ production is 
prominently upregulated [16,17]. In the absence of liganded TRβ, the negative cofactor 
is absent, and GATA2/Pit1-led transcriptional activation predominates in our model (Fig. 
4).  
  
In one study, TRβ associated with GATA2 and acted in a similar manner as 
nTRE-associated TRβ [6]. In this situation, MED1 recruitment to DNA-bound GATA2 
occurs in two ways: direct interaction between GATA2 and N-terminal MED1(1–530) 
and indirect interaction with the LxxLL domain of MED1 and GATA2 mediated by 
liganded TRβ. The additional possibility of MED1 LxxLL-mediated and TRβ-mediated 
recruitment of Mediator enhances the likelihood that a functional PIC forms for 
effective transcriptional initiation.  
  
In conclusion, MED1 acts a positive cofactor in T3-independent and T3-dependent 
manners on the promoter of gene encoding TSHβ. The multiple modes of MED1 
recruitment to the promoter contribute to the fine-tuning of the physiological 
homeostasis of the pituitary-thyroid axis and might contribute to some pathological 
conditions.  
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Figure legends 
 
Fig. 1. Reduced thyroid hormone reservoir and pituitary TSHβ gene transcription in 
MED1(LX) KI mice.  
(A)Serum levels of free T3 and free T4 were measured in five 12-week-old male mice 
of each genotype. Values are the mean ± SD of a representative experiment (*P < 0.05; 
**P < 0.01).  
(B)Northern blot of pooled pituitary total RNA from the same mice. The relative signal 
intensities of RNA blot analyses were quantified with an image analyzer, and the 
expression of each mRNA (normalized to the level of actin mRNA) was expressed as 
the fold increase versus the value in wild-type mice. A decrease in the TSHβ signal was 
observed in MED1(LX) homozygous knock-in mice, but the signals for the common α 
subunit and two other β subunits that use the common α subunit (FSHβ and LHβ) did 
not change. The signals in heterozygous knock-in mice did not change either. These 
results were reproduced in three independent experiments.  
  
Fig. 2. MED1 is a positive cofactor for GATA2 and Pit1 on the TSHβ gene promoter.  
(A) A luciferase reporter assay in CV-1 cells showed that GATA2 and Pit1 cooperatively 
enhanced THSB promoter activity.  
(B) A luciferase reporter assay in Med
−/− 
MEFs showed that GATA2 and Pit1 
cooperatively enhanced TSHB promoter activity in the absence of MED1. The promoter 
activity was further enhanced in the presence of MED1.  
(C, D) Mammalian two-hybrid assays using Med1
−/−
 MEFs showed that both Pit1 (C) 
and GATA2 (D) specifically interacted with the N-terminal fragment MED1(1–530). (E, 
F) Quantitative RT-PCR (E) and western blot (F) of MED1 2 days after transfection of 
Med1
+/+
 MEFs with MED1 siRNA.  
(G) A luciferase reporter assay in Med1
+/+
 MEFs showed that MED1(1–530) as well as 
full-length MED1 enhanced GATA2- and Pit1-mediated transcription. Both 
siRNA-resistant MED1(1–530) and full-length MED1 rescued the reporter activity 
attenuated by MED1 siRNA.  
The means ± SD from a representative experiment performed in triplicate are shown  
(A–F). Values were plotted as the fold increase versus the value without GATA2 or Pit1 
(A, B), versus the value with Gal-MED1(1–530) and VP16 (C, D), versus the value of 
control scrambled siRNA (E), or versus the value with GATA2 and Pit1 (F).  
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Fig. 3. MED1 is a T3-dependent positive cofactor on the TSHβ gene promoter.  
(A) In a luciferase reporter assay in Med1
−/−
 MEFs, wild-type MED1 enhanced TSHB 
promoter activity in a T3-dependent manner, but MED1(LX-mutant) or MED1(1–530) 
did not.  
(B, C) Quantitative RT-PCR (B) and western blot (C) of SRC1, SRC2, and HDAC2 2 
days after transfection of Med1
−/−
 MEFs with SRC1/SRC2 and/or HDAC2 siRNA.  
(D) In a luciferase reporter assay in Med1
−/−
 MEFs, MED1 further enhanced 
T3-dependent TSHB promoter activity when SRC1/SRC2 or HDAC2 expression was 
suppressed. The reporter activity was tested in the presence of GATA2 and Pit1 with 
either scrambled siRNA or siRNA for SRC1/SRC2 and/or HDAC2.  
The means ± SD from a representative experiment performed in triplicate are shown (A, 
B, D). The values were plotted as the fold increase versus the value with TRβ and 
without T3 (A), versus the value of control scrambled siRNA (B), or versus the value 
with GATA2, Pit1, and scrambled siRNA (D).  
  
Fig. 4. Regulation of the TSHβ gene promoter by MED1 in the presence of T3.   
The following specific sites are present on the TSHB promoter: Pit1-binding site (−120 
to −108) [18], GATA2-binding sites (−107 to −102, −96 to −91) [12,19], TATA box 
(−29 to −24) [20], and nTRE (−2 to +33) [21-25]. MED1 is recruited to the TSHB 
promoter either through the ligand-independent interaction of N-terminal MED1(1–530) 
with GATA2 or Pit1 or through the ligand-dependent interaction of the LxxLL motifs of 
MED1 with the AF2 domain of liganded TRβ. The AF2 domain of liganded TRβ binds 
to the negative cofactor SRC1/SRC2 or the positive cofactor MED1 in a mutually 
exclusive, and probably competitive, manner. Liganded TRβ also recruits the negative 
cofactor HDAC2. LxxLL-mediated recruitment of MED1 to the THSB promoter may 
facilitate the interaction of MED1(1–530) with GATA2 and stabilize Mediator 
recruitment to the promoter and the subsequent formation of a functional preinitiation 
complex (PIC) during promoter melting. The involvement of multiple activators and 
both positive and negative cofactors may fine-tune the ligand-dependent negative 
feedback mechanism of THSβ production. 
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